Test Your Knowledge

Back to C. difficile & Microbiome Therapeutics Knowledge Hub

1. What are the most common risk factors for Clostridioides difficile infection (CDI) outside of the hospital setting?
2. According to current guidelines from the American College of Gastroenterology, which of the following are recommended for the initial treatment of severe Clostridioides difficile infection (CDI)?
   Note: Current guidelines define severe CDI in patients with white blood cell count ≥15,000 cells/mm3 or serum creatinine >15 mg/dL.1
3. Approximately what percentage of patients will experience an initial recurrence of Clostridioides difficile infection (CDI) after their first treatment?
4. What are the hypothesized mechanisms underlying the effects of fecal microbiota transplant (FMT, or intestinal microbiota transplant [IMT]) and live biotherapeutic products in patients with inflammatory bowel disease?
5. What are the perceived benefits of developing cultured live biotherapeutics for the treatment of recurrent Clostridioides difficile infection (CDI)?

A. Antibiotic treatment B. Inflammatory bowel disease C. Lung disease D. A and B only

A. Oral metronidazole B. Vancomycin C. Fecal microbiota transplantation D. Bezlotoxumab

A. 10% B. 15% C. 20% D. 25%

A. Restore microbiota diversity B. Restore microbiota function C. Restore intestinal barrier function D. All of the above

A. Preparation using good manufacturing practice B. Standardization of bacterial components C. Elimination of donor screening D. All of the above

Submit